triamterene Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2728 396-01-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • triamterene
  • diurene
  • pterofen
  • pterophene
  • triamteren
  • triamteril
  • triteren
A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.
  • Molecular weight: 253.27
  • Formula: C12H11N7
  • CLOGP: 1.61
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 129.62
  • ALOGS: -2.42
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.03 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.15 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 63 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.42 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 10, 1964 FDA CONCORDIA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Crystal nephropathy 49.89 11.41 18 26266 843 53321939
Blood potassium decreased 44.37 11.41 75 26209 40385 53282397
Exposure during pregnancy 44.03 11.41 5 26279 124855 53197927
Synovitis 41.58 11.41 3 26281 107890 53214892
Hyponatraemic encephalopathy 37.23 11.41 11 26273 271 53322511
Acquired haemophilia 37.15 11.41 15 26269 957 53321825
Systemic lupus erythematosus 35.50 11.41 9 26275 125405 53197377
Lower respiratory tract infection 33.75 11.41 3 26281 90978 53231804
Off label use 32.13 11.41 122 26162 472090 52850692
Myocardial infarction 31.41 11.41 114 26170 99240 53223542
Rheumatoid arthritis 31.10 11.41 68 26216 314463 53008319
Cerebrovascular accident 29.38 11.41 116 26168 105058 53217724
Hand deformity 28.44 11.41 4 26280 84845 53237937
Oedema peripheral 28.38 11.41 162 26122 170625 53152157
Gastrooesophageal reflux disease 27.97 11.41 97 26187 82566 53240216
Coronary artery disease 27.81 11.41 55 26229 33382 53289400
Cardiac failure congestive 27.28 11.41 104 26180 92653 53230129
Osteoarthritis 26.76 11.41 86 26198 70400 53252382
Dizziness 26.04 11.41 289 25995 371970 52950812
Hyponatraemia 25.80 11.41 114 26170 108493 53214289
Drug intolerance 25.11 11.41 39 26245 205454 53117328
Pyrexia 24.38 11.41 109 26175 403084 52919698
Hypokalaemia 24.22 11.41 103 26181 96414 53226368
Drug ineffective 23.88 11.41 273 26011 816972 52505810
Intentional overdose 22.92 11.41 3 26281 67202 53255580
Focal segmental glomerulosclerosis 22.00 11.41 12 26272 1513 53321269
Glossodynia 21.91 11.41 11 26273 100280 53222502
Infusion related reaction 20.62 11.41 28 26256 155929 53166853
Feeling abnormal 20.31 11.41 125 26159 135176 53187606
Ventricular tachycardia 19.56 11.41 33 26251 17729 53305053
C-reactive protein increased 18.96 11.41 5 26279 67881 53254901
Product use issue 18.51 11.41 25 26259 139559 53183223
Thinking abnormal 18.00 11.41 24 26260 10484 53312298
Neutropenia 17.78 11.41 32 26252 159153 53163629
Blood pressure increased 17.58 11.41 124 26160 140355 53182427
Diabetic neuropathy 17.33 11.41 15 26269 4012 53318770
Myocardial ischaemia 17.08 11.41 26 26258 12818 53309964
Transient ischaemic attack 16.78 11.41 47 26237 35678 53287104
Transient acantholytic dermatosis 16.63 11.41 4 26280 43 53322739
Depression 16.57 11.41 150 26134 182902 53139880
Insomnia 16.28 11.41 152 26132 186920 53135862
Product dose omission issue 15.83 11.41 154 26130 191466 53131316
Product use in unapproved indication 15.00 11.41 20 26264 112269 53210513
Febrile neutropenia 14.73 11.41 18 26266 104918 53217864
Appetite disorder 14.49 11.41 17 26267 6526 53316256
Oedema 14.00 11.41 73 26211 74273 53248509
Anxiety 13.84 11.41 153 26131 196551 53126231
Asthenia 13.51 11.41 241 26043 343349 52979433
General physical health deterioration 13.50 11.41 33 26251 146909 53175873
Myalgia 13.43 11.41 112 26172 133379 53189403
Skin discolouration 13.41 11.41 43 26241 35149 53287633
Therapeutic product effect decreased 13.38 11.41 26 26258 125629 53197153
Deep vein thrombosis 13.33 11.41 78 26206 82835 53239947
Carpal tunnel syndrome 13.32 11.41 28 26256 17739 53305043
Dry skin 13.19 11.41 51 26233 45709 53277073
Intentional product use issue 13.00 11.41 10 26274 72484 53250298
Vitamin B6 deficiency 12.92 11.41 4 26280 116 53322666
Lacunar infarction 12.79 11.41 12 26272 3562 53319220
Hyperlipidaemia 12.64 11.41 29 26255 19486 53303296
Wound 12.54 11.41 16 26268 91541 53231241
Suicide attempt 11.80 11.41 7 26277 58161 53264621
Overdose 11.72 11.41 22 26262 107714 53215068
Back pain 11.70 11.41 171 26113 234076 53088706

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product packaging quantity issue 62.50 14.61 18 8128 813 32504567
Coronary artery disease 36.31 14.61 53 8093 49653 32455727
Myocardial infarction 35.17 14.61 89 8057 125587 32379793
Cerebrovascular accident 27.17 14.61 64 8082 86256 32419124
Dizziness 25.56 14.61 112 8034 209506 32295874
Cardiac failure congestive 20.56 14.61 57 8089 84795 32420585
Lymphopenia 19.55 14.61 21 8125 14435 32490945
Angioedema 18.67 14.61 33 8113 36256 32469124
Completed suicide 17.54 14.61 57 8089 92460 32412920
Activated partial thromboplastin time prolonged 16.49 14.61 15 8131 8440 32496940
Off label use 16.01 14.61 33 8113 306287 32199093
Electrocardiogram U wave present 15.40 14.61 3 8143 23 32505357
Ulcer haemorrhage 15.16 14.61 9 8137 2633 32502747
Bundle branch block left 14.83 14.61 12 8134 5767 32499613

Pharmacologic Action:

SourceCodeDescription
ATC C03DB02 CARDIOVASCULAR SYSTEM
DIURETICS
ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
Other potassium-sparing agents
FDA PE N0000008859 Decreased Renal K+ Excretion
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175418 Potassium-sparing Diuretic
MeSH PA D004232 Diuretics
MeSH PA D062686 Epithelial Sodium Channel Blockers
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D026941 Sodium Channel Blockers
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:38633 Na channel blocker

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Peripheral Edema due to Chronic Heart Failure indication
Pulmonary Edema due to Chronic Heart Failure indication
Hypokalemia off-label use 43339004
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Acidosis contraindication 51387008
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Azotemia contraindication 445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.22 Basic
pKa2 5.5 Basic
pKa3 2.21 Basic
pKa4 0.54 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amiloride-sensitive sodium channel, ENaC Ion channel BLOCKER IC50 5.30 IUPHAR CHEMBL
Solute carrier family 12 member 1 Transporter WOMBAT-PK
Cytochrome P450 2D6 Enzyme IC50 5 DRUG MATRIX
Caspase-1 Enzyme IC50 5.44 DRUG MATRIX
Cathepsin G Enzyme IC50 5.13 DRUG MATRIX
Pteridine reductase 1 Enzyme Ki 5.47 CHEMBL

External reference:

IDSource
4017902 VUID
N0000146253 NUI
D00386 KEGG_DRUG
4017902 VANDF
C0040869 UMLSCUI
CHEBI:9671 CHEBI
DX2 PDB_CHEM_ID
CHEMBL585 ChEMBL_ID
DB00384 DRUGBANK_ID
D014223 MESH_DESCRIPTOR_UI
1266 INN_ID
5546 PUBCHEM_CID
4329 IUPHAR_LIGAND_ID
WS821Z52LQ UNII
10763 RXNORM
5617 MMSL
80875 MMSL
d00396 MMSL
002315 NDDF
12512008 SNOMEDCT_US
387053007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MAXZIDE HUMAN PRESCRIPTION DRUG LABEL 2 0378-0460 TABLET 75 mg ORAL NDA 20 sections
MAXZIDE-25 HUMAN PRESCRIPTION DRUG LABEL 2 0378-0464 TABLET 37.50 mg ORAL NDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-1352 TABLET 37.50 mg ORAL NDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-1355 TABLET 75 mg ORAL NDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-2537 CAPSULE 37.50 mg ORAL ANDA 21 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0527-1632 CAPSULE 37.50 mg ORAL ANDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0591-0348 TABLET 75 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0591-0424 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0615-1333 CAPSULE 37.50 mg ORAL ANDA 23 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0615-3583 TABLET 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0781-2074 CAPSULE 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0781-2715 CAPSULE 50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10135-581 CAPSULE 37.50 mg ORAL ANDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-049 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-076 TABLET 37.50 mg ORAL NDA 22 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-080 TABLET 75 mg ORAL ANDA 23 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-536 TABLET 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 10544-537 TABLET 75 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 16590-338 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 21695-496 TABLET 37.50 mg ORAL ANDA 21 sections
Triamterene hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 21695-497 TABLET 75 mg ORAL ANDA 21 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 21695-839 CAPSULE 37.50 mg ORAL ANDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 33261-365 TABLET 75 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 33261-952 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 35356-974 CAPSULE 37.50 mg ORAL ANDA 24 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 42291-841 CAPSULE 37.50 mg ORAL ANDA 20 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 42291-842 TABLET 37.50 mg ORAL ANDA 19 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43063-424 TABLET 37.50 mg ORAL NDA 23 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 45865-402 CAPSULE 37.50 mg ORAL ANDA 24 sections
Triamterene and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 50090-0372 TABLET 75 mg ORAL ANDA 19 sections